Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202606005 Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination with Multiple Agents in Subjects with Advanced Solid Tumors New Drug Phase Ⅰ
N202606011 A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4) New Drug Phase Ⅲ
N202606012 A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants with Immunoglobulin A Nephropathy (JUNIPER) New Drug Phase Ⅱ
N202606013 A randomized, open-label (unblinding), crossover bioequivalence study to compare two apremilast F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202606020 Double Stents for A Severe Myocardial Bridging Lesion with Significant Hemodynamic Abnormality New Medical Technology NA
N202606021 Optimization of oral cancer prevention and control through integration of early risk prediction models and artificial intelligence–assisted screening New Medical Device NA
N202606023 Assessing Large Language Models for First-Contact Clinical Decision Support for patients in Gynecology: A Double-Blinded Study New Medical Device NA
1 2 43 44 45 46 47 48 49 50 51 52 / 52

TOP